{"id":"W4403978864","doi":"10.1093/ecco-jcc/jjae164","title":"Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies","year":2024,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; University of Calgary","funders":"Cilag; Genentech; Sanofi; Kyowa Hakko Kirin; Eisai; Celltrion; National Institutes of Health; Mylan; Ironwood Pharmaceuticals, Incorporated; Kenneth Rainin Foundation; EA Pharma Co., Ltd.; Teva Pharmaceutical Industries; Leona M. and Harry B. Helmsley Charitable Trust; Novo Nordisk; Gilead Sciences; Amgen; ActoGeniX; Celgene; Pfizer; Biogen; GlaxoSmithKline; Dr. Falk Pharma; Celltrion Healthcare; Allergan; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Calprotectin; Crohn's disease; Biomarker; Normalization (sociology); Internal medicine; Crohn disease; Disease; Gastroenterology; Inflammatory bowel disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004121582,0.0003922349,0.001314433,0.0001756106,0.0001782465,0.0007451,0.0002773421,0.0006841779,0.0008542777],"category_scores_gemma":[0.003608576,0.0002749444,0.00180821,0.0002495783,0.000367125,0.0004418416,0.0002969472,0.001004905,0.0001465307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003006186,"about_ca_system_score_gemma":0.0004754272,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003473023,"about_ca_topic_score_gemma":0.0008312371,"domain_scores_codex":[0.9988033,0.0006660107,0.00009773346,0.0001259409,0.0002129983,0.0000940715],"domain_scores_gemma":[0.9948406,0.001798861,0.002034952,0.0004041235,0.0004050258,0.0005165484],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6300011,0.005743499,0.1880329,0.001369629,0.005956794,0.0001779184,0.0004454915,0.001225983,0.01470606,0.0001825449,0.002552054,0.149606],"study_design_scores_gemma":[0.08923165,0.2117116,0.6773412,0.0002009563,0.00684326,0.0006225992,0.0002104916,0.001904254,0.005363809,0.0002047957,0.006281892,0.00008357826],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943703,0.004295126,0.0001349537,0.0001816304,0.00002927385,0.00009727186,0.0002512974,0.00001747106,0.0006228345],"genre_scores_gemma":[0.9977967,0.0009642886,0.0002839193,0.0001791789,0.00006732063,0.00005998543,0.0004231196,0.000005597614,0.0002199646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004121582,"threshold_uncertainty_score":0.0217973,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006751730623852491,"score_gpt":0.2514586276878908,"score_spread":0.2447068970640384,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}